Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “buy” rating reissued by research analysts at Canaccord Genuity in a research note issued to investors on Saturday. They presently have a $10.00 price target on the stock. Canaccord Genuity’s price target would indicate a potential upside of 112.77% from the company’s current price.

A number of other equities analysts also recently commented on AUPH. HC Wainwright started coverage on shares of Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They set a “buy” rating and a $7.00 target price for the company. Leerink Swann reiterated an “outperform” rating and set a $7.00 target price on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. Finally, FBR & Co reiterated an “outperform” rating and set a $9.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, August 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $7.75.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The firm’s market capitalization is $165.84 million. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $5.69. The stock’s 50 day moving average price is $2.45 and its 200-day moving average price is $2.78.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Abingworth LLP increased its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 479.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 512,036 shares of the company’s stock after buying an additional 423,729 shares during the period. Aurinia Pharmaceuticals comprises 1.5% of Abingworth LLP’s holdings, making the stock its 16th largest position. Abingworth LLP owned about 1.56% of Aurinia Pharmaceuticals worth $1,388,000 at the end of the most recent reporting period. 20.04% of the stock is currently owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.